Prognostic Markers of Post-Stroke Depression (PROMoSD)

Sponsor
Ruhr University of Bochum (Other)
Overall Status
Recruiting
CT.gov ID
NCT05580198
Collaborator
(none)
105
1
25.9
4.1

Study Details

Study Description

Brief Summary

Single-center prospective observational study investigating the association of brainstem raphe hypoechogenicity detected by transcranial sonography and post-stroke depression three months after an acute ischemic stroke.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: Transcranial sonography.

Detailed Description

Post-stroke depression (PSD) is an important complication after a stroke. Despite significant limitations between studies of PSD risk factors, stroke severity or post-stroke disability, prior depressive episodes, and female sex are arguably the most well-known risk factors for developing PSD, although the predictive value of these factors is limited.

A hypoechogenic brainstem raphe (BR) detected by transcranial sonography (TCS) is associated with depressive symptoms in distinct diseases but is also common with approximately 25% of the non-depressed population in Europe. The primary aim of this study is to investigate the association between BR hypoechogenicity and PSD occurrence in a prospective observational study design.

Study Design

Study Type:
Observational
Anticipated Enrollment :
105 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Prognostic Markers of Post-Stroke Depression: A Single-center Prospective Observational Study
Actual Study Start Date :
Jan 1, 2021
Anticipated Primary Completion Date :
Nov 1, 2022
Anticipated Study Completion Date :
Mar 1, 2023

Arms and Interventions

Arm Intervention/Treatment
BRH+

Acute ischemic stroke patients with brainstem raphe hypoechogenicity.

Diagnostic Test: Transcranial sonography.
Transcranial sonography examination to determine the brainstem raphe echogenicity.

BRH-

Acute ischemic stroke patients without brainstem raphe hypoechogenicity.

Diagnostic Test: Transcranial sonography.
Transcranial sonography examination to determine the brainstem raphe echogenicity.

Outcome Measures

Primary Outcome Measures

  1. Post-stroke depression [3 months]

    PSD diagnosis was defined according to the fifth version of the Diagnostic and Statistical Manual of Mental Disorders (DSM-V criteria) or by any new medication for anti-depressive indication during follow-up

Secondary Outcome Measures

  1. Severity of depressive symptoms [3 months]

    Measured by the Hamilton Depression Rating Scale (HRSD, minimum score: 0, maximum score: 52), with higher scores indicating greater severity of depressive symptoms.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Acute ischemic stroke with the onset of symptoms within the past 14 days

  • Diagnosis of AIS is confirmed by brain imaging, either computer tomography or magnetic resonance imaging

Exclusion Criteria:
  • Insufficient transtemporal bone window for transcranial sonography examination

Contacts and Locations

Locations

Site City State Country Postal Code
1 St. Josef-Hospital Bochum Bochum Nordrhein-Westfalen Germany 44791

Sponsors and Collaborators

  • Ruhr University of Bochum

Investigators

  • Principal Investigator: Christos Krogias, Prof., St. Josef-Hospital Bochum, Ruhr-University Bochum

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Christos Krogias, Prof. Dr., Ruhr University of Bochum
ClinicalTrials.gov Identifier:
NCT05580198
Other Study ID Numbers:
  • 20-6862
First Posted:
Oct 14, 2022
Last Update Posted:
Oct 17, 2022
Last Verified:
Oct 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 17, 2022